Panettiere F J, Leichman L, O'Bryan R, Haas C, Fletcher W
Cancer Clin Trials. 1981;4(1):29-31.
The southwest oncology group tested cis-platinum, given in 28-day courses of 50 mg/m2 twice, a week apart, in patients with epidermoid carcinoma of the esophagus. Currently 19 patients entered on the study are evaluable for response (15 fully evaluable). Of these, two attained complete disappearance of tumor and four had partial responses. Of the remainder, two had stable disease lasting in excess of 90 days. Hematologic toxicity has been minimal except that three patients required multiple blood transfusions for anemia not due to blood loss. Of 21 patients currently evaluable for renal toxicity, nine had mild, and three had moderate azotemia. These results suggest that, unlike what has been believed in the past, squamous cell carcinoma of the esophagus is not a chemotherapy-resistant tumor. Further evaluation of cis-platinum alone and in combination with radiotherapy and surgery are in progress.
西南肿瘤协作组对食管鳞状细胞癌患者进行了顺铂治疗试验，给药方案为每28天一次，每次50mg/m²，每周两次，间隔一周。目前，参与该研究的19例患者可进行疗效评估（15例可完全评估）。其中，2例患者肿瘤完全消失，4例部分缓解。其余患者中，2例病情稳定持续超过90天。血液学毒性极小，只有3例患者因非失血导致的贫血需要多次输血。在目前可评估肾毒性的21例患者中，9例轻度肾毒性，3例中度氮质血症。这些结果表明，与过去的认识不同，食管鳞状细胞癌并非化疗耐药肿瘤。顺铂单药以及与放疗和手术联合应用的进一步评估正在进行中。
